Revenue
2020
2021
2022
2023
2024
2025
Ovid Therapeutics Inc. (OVID)
Price$2.78Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $566,000 | $392,000 | $1.5M | $208.4M | $12.6M | — | — | — | — | — |
| Research & development | $25.6M | $36.8M | $28.6M | $24.6M | $46.9M | $63.4M | $42.2M | $33.8M | $50.0M | $9.6M | $6.6M |
| Operating expenses | $49.7M | $62.5M | $59.7M | $57.1M | $84.2M | $94.0M | $61.4M | $52.9M | $65.0M | $22.5M | $13.2M |
| Operating income | −$42.4M | −$61.9M | −$59.3M | −$55.5M | $124.2M | −$81.4M | −$61.4M | −$52.9M | −$65.0M | −$22.5M | −$13.2M |
| Operating margin | −585.20% | −10,933.75% | −15,122.70% | −3,696.44% | 59.61% | −645.40% | — | — | — | — | — |
| EBITDA | −$42.2M | −$61.3M | −$58.7M | −$55.0M | $124.4M | −$81.1M | −$61.2M | −$52.8M | −$64.9M | −$22.5M | −$13.2M |
| EBITDA margin | −581.44% | −10,825.44% | −14,977.81% | −3,662.33% | 59.72% | −642.96% | — | — | — | — | — |
| Net income | −$17.4M | −$26.4M | −$52.3M | −$54.2M | $122.8M | −$81.0M | −$60.5M | −$52.0M | −$64.8M | −$22.4M | −$13.2M |
| Net profit margin | −240.13% | −4,670.14% | −13,351.79% | −3,604.66% | 58.95% | −642.26% | — | — | — | — | — |
| Basic EPSper basic share | -$0.23 | -$0.37 | -$0.74 | -$0.77 | $1.78 | -$1.39 | — | -$2.11 | -$3.35 | -$2.28 | -$1.36 |
| Diluted EPSper diluted share | -$0.23 | -$0.37 | -$0.74 | -$0.77 | $1.76 | -$1.39 | — | -$2.11 | -$3.35 | -$2.28 | -$1.36 |
Owners
Reported shareholders
11.23%of listed shares
Jupiter Topco LLC20.74M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 11.23%20.74M shares |
EVENTIDE ASSET MANAGEMENT, LLC | 6.39%11.81M shares |
BlackRock, Inc. | 5.86%10.82M shares |
RA CAPITAL MANAGEMENT, L.P. | 5.68%10.5M shares |
Affinity Asset Advisors, LLC | 5.49%10.14M shares |
Takeda Pharmaceuticals U.S.A., Inc. / TAKEDA PHARMACEUTICAL CO LTD | ≈4.75%8.78M shares |
STATE STREET CORP | 4.28%7.9M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.20%7.76M shares |
ADAR1 Capital Management, LLC | 4.01%7.42M shares |
Balyasny Asset Management L.P. | 3.64%6.72M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.34%6.16M shares |
FEDERATED HERMES, INC. | 3.22%5.95M shares |
BRAIDWELL LP | 3.20%5.92M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.20%4.07M shares |
LEVIN JEREMY M | ≈2.04%3.77M shares |
SILVERARC CAPITAL MANAGEMENT, LLC | 1.68%3.1M shares |
STEMPOINT CAPITAL LP | 1.31%2.42M shares |
Ikarian Capital, LLC | 1.23%2.27M shares |
Point72 Asset Management, L.P. | 1.05%1.95M shares |
SPHERA FUNDS MANAGEMENT LTD. | 0.73%1.35M shares |
Percentages use 184.76M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 23, 2026Form 4 | ALEXANDER MARGARET A.President and CEO | SellCommon Stock | 11.7K | $1.45 | $16.9K | 61.8K |
| Feb 23, 2026Form 4 | Rona Jeffrey ACBFO | SellCommon Stock | 8.5K | $1.45 | $12.4K | 88.2K |
| Dec 11, 2025Form 4 | LEVIN JEREMY MCEO | BuySeries B Warrant (right to buy) · derivative | 35.5K | — | — | 35.5K |
| Dec 11, 2025Form 4 | LEVIN JEREMY MCEO | BuySeries A Warrant (right to buy) · derivative | 47.3K | — | — | 47.3K |
| Dec 11, 2025Form 4 | LEVIN JEREMY MCEO | BuySeries B Convertible Preferred Stock · derivative | 71 | — | — | 71 |